Search Result

Results for "

dysregulated

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Antibiotic (4) Apoptosis (8) Aryl Hydrocarbon Receptor (2) Atg7 (1) Atg8/LC3 (1) Aurora Kinase (1) Autophagy (4) Bacterial (4) Bcl-2 Family (1) Cadherin (1) Calcium Channel (4) Caspase (1) CDK (2) Ceramidase (1) Deubiquitinase (1) DNA/RNA Synthesis (1) ERK (2) Estrogen Receptor/ERR (1) Fluorescent Dye (1) Histone Demethylase (1) IAP (1) IFNAR (2) Interleukin Related (1) Isotope-Labeled Compounds (2) Ligands for E3 Ligase (1) MASTL (1) MEK (1) Mitochondrial Metabolism (1) NF-κB (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (1) PDK-1 (1) PI3K (1) PROTACs (1) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) RGS Protein (1) SARS-CoV (6) Ser/Thr Kinase (1) Ser/Thr Protease (1) Sodium Channel (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (3) TRP Channel (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (4) Endocrinology (1) Infection (5) Inflammation/Immunology (13) Metabolic Disease (2) Neurological Disease (4)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (1)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0170

Trovafloxacin Maximum Cited Publications 7 Publications Verification	Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-103399

Trovafloxacin mesylate Maximum Cited Publications 7 Publications Verification	Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-B0926A

Sodium diatrizoate Diatrizoic acid sodium salt; Sodium amidotrizoate	Apoptosis	Inflammation/Immunology
Sodium diatrizoate (Diatrizoic acid sodium salt) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Sodium diatrizoate induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium .

HY-B0926

Diatrizoic acid Diatrizoate; Amidotrizoic acid	Apoptosis	Inflammation/Immunology
Diatrizoic acid (Diatrizoate) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Diatrizoic acid induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium .

HY-137978A

Ezurpimtrostat hydrochloride 3 Publications Verification GNS561 hydrochloride	SARS-CoV IFNAR Autophagy Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-N6670

Cefotetan	Antibiotic Raf ERK Ras MEK Bacterial	Infection
Cefotetan is a binding agent that targets human Raf1 kinase inhibitor protein (hRKIP). Cefotetan binds to hRKIP, reduces the binding space between hRKIP and Raf1 kinase, relieves hRKIP's inhibition of the Ras/Raf1/MEK/ERK signaling pathway, and enhances ERK phosphorylation. Cefotetan can be used to study diseases associated with dysregulated Ras/Raf1/MEK/ERK signaling pathways. Cefotetan is also a broad-spectrum antibacterial agent that disrupts cell wall synthesis by binding to bacterial penicillin-binding proteins (PBPs). It is used to study bacterial infections such as bone, skin, urinary tract, and lower respiratory tract .

HY-W011725

N-6-Methyl-2-deoxyadenosine m6dA	Nucleoside Antimetabolite/Analog Mitochondrial Metabolism DNA/RNA Synthesis	Neurological Disease Cancer
N-6-Methyl-2-deoxyadenosine (m6dA) is an adenine nucleoside analogue. N-6-Methyl-2-deoxyadenosine targets nuclear processes and DNA replication machineries including WER, SATB1, TFAM, Jumu, SSBP1, DNA polymerase η and phage polymerase Gp90 exo ⁻. N-6-Methyl-2-deoxyadenosine acts as a multifunctional epigenetic regulator that modulates transcription, DNA damage response, cell cycle, transposon silencing, stress adaptation, epigenetic crosstalk, and nucleosome organization in both prokaryotes and eukaryotes. N-6-Methyl-2-deoxyadenosine regulates mitochondrial epigenetic inheritance and is required for fear extinction memory in mice. N-6-Methyl-2-deoxyadenosine exhibits dysregulated levels in cancers. N-6-Methyl-2-deoxyadenosine can be used for the research of glioblastoma, triple negative breast cancer, and conditioned fear (fear extinction impairment) .

HY-12502A

Efonidipine hydrochloride monoethanolate 1 Publications Verification NZ-105 hydrochloride monoethanolate; (±)-Efonidipine hydrochloride monoethanolate	Calcium Channel SARS-CoV	Cardiovascular Disease Neurological Disease Cancer
Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-111449

BAY-218 2 Publications Verification AHR antagonist 1	Aryl Hydrocarbon Receptor	Inflammation/Immunology Cancer
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC₅₀ of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses .

HY-153468

ErSO-TFPy TEQ103; Sera2	Sodium Channel TRP Channel	Cancer
ErSO-TFPy (TEQ103) is an ERα+ tumor cell inhibitor with low nanomolar cytotoxic activity against ERα+ breast cancer cells. ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy dysregulates calcium homeostasis in ERα+ tumor cells, triggers the anticipatory unfolded protein response, and induces rapid immune cell-independent necrotic cell death. ErSO-TFPy can be used for the research of estrogen receptor alpha positive breast cancer .

HY-171658

R1-ICR-5	PROTACs Ser/Thr Kinase TNF Receptor Toll-like Receptor (TLR) NF-κB p38 MAPK	Inflammation/Immunology Cancer
R1-ICR-5 is a highly selective RIPK1 PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the TNFR1 and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes RIPK3 activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation .

HY-112181

KO-947 4 Publications Verification	ERK	Cancer
KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors.

HY-12502

Efonidipine 1 Publications Verification NZ-105; (±)-Efonidipine	Calcium Channel SARS-CoV	Cardiovascular Disease Neurological Disease Cancer
Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 main protease. Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-137978

Ezurpimtrostat 3 Publications Verification GNS561	SARS-CoV IFNAR Autophagy Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-135831

AHR antagonist 2 1 Publications Verification	Aryl Hydrocarbon Receptor	Inflammation/Immunology Cancer
AHR antagonist 2 (Example 1) is a potent aryl hydrocarbon receptor (AHR) antagonist with IC₅₀s of 885 pM and 2.03 nM for human and mouse AHR. AHR antagonist 2 can be used for the studies of cancers and imbalance of the immune response .

HY-178521

BAS00602705	Cadherin	Cancer
BAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC) .

HY-147600

CDK7-IN-15	CDK	Cancer
CDK7-IN-15 (Compound 8) is a selective CDK7 inhibitor with an IC₅₀ greater than 10 nM and less than or equal to 100 nM. CDK7-IN-15 is applicable to the research of cancers associated with transcriptional dysregulation .

HY-136540

Resolvin D3 RvD3	AMPK Autophagy	Inflammation/Immunology
Resolvin D3 (RvD3) is a docosahexaenoic acid (DHA) derived mediator. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation .

HY-W231513

MASTL/Aurora A-IN-1	MASTL Ser/Thr Protease Aurora Kinase	Cancer
MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC₅₀ values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI₅₀ values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .

HY-12502B

Efonidipine hydrochloride NZ-105 hydrochloride; (±)-Efonidipine hydrochloride	Calcium Channel SARS-CoV	Cardiovascular Disease Cancer
Efonidipine (NZ-105) hydrochloride is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-153895

SLU-PP-1072	Estrogen Receptor/ERR	Endocrinology
SLU-PP-1072 is a dual ERRα/γ inverse agonist, used in Prostate cancer (PCa) research. SLU-PP-1072 disrupts PCa cell metabolism, and induces apoptosis via dysregulating cell cycle .

HY-P99846

Dectrekumab QAX576	Interleukin Related	Inflammation/Immunology
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .

HY-N15826

RBM1-151	Fluorescent Dye Ceramidase	Cancer
RBM1-151, a 1-deoxy derivative and vinilog of RBM14-C12 (HY-150163), as a fluorogenic substrate of Amidases (HY-P2736) (E_x/E_m). RBM1-151 is hydrolyzed by acid ceramidase (AC) (( ^appK_m = 7.0 μM; ^appV_max = 99.3 nM/min), N-acylethanolamine-hydrolyzing acid amidase ( ^appK_m = 0.73 μM; ^appV_max = 0.24 nM/min), and fatty Acid amide hydrolase (FAAH) ( ^appK_m = 3.6 μM; ^appV_max = 7.6 nM/min) but not by other ceramidases. RBM1-151 is applicable for basic biological studies of lipid amidase function, as well as potential diagnostic/prognostic evaluations of diseases involving dysregulated AC, NAAA, or FAAH (Farber disease, cancer) .

HY-156001

DUB-IN-7	Deubiquitinase	Cancer
DUB-IN-7 (compound 43) is a Deubiquitinating enzymes (DUBs) inhibitor. DUB-IN-7 can be used in the study of diseases mediated by dysregulated JAK2 activity, such as leukemia .

HY-136540S

Resolvin D3-d5 RvD3-d₅	Isotope-Labeled Compounds	Inflammation/Immunology
Resolvin D3-d₅ is the deuterium labeled Resolvin D3. Resolvin D3 (RvD3) is a docosahexaenoic acid (DHA) derived mediator. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation .

HY-B0926R

Diatrizoic acid (Standard) Diatrizoate (Standard); Amidotrizoic acid (Standard)	Reference Standards Apoptosis	Inflammation/Immunology
Diatrizoic acid (Standard) is the analytical standard of Diatrizoic acid. This product is intended for research and analytical applications. Diatrizoic acid (Diatrizoate) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Diatrizoic acid induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium .

HY-B0926AR

Sodium diatrizoate (Standard) Diatrizoic acid sodium salt (Standard); Sodium amidotrizoate (Standard)	Reference Standards Apoptosis	Inflammation/Immunology
Sodium diatrizoate (Standard) is the analytical standard of Sodium diatrizoate. This product is intended for research and analytical applications. Sodium diatrizoate (Diatrizoic acid sodium salt) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Sodium diatrizoate induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

HY-122251

CCG-4986	RGS Protein	Others Neurological Disease
CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS4. CCG-4986 can be used to study diseases related to dysregulated G protein-coupled receptor (GPCR) signaling, such as Parkinson's disease and opioid addiction .

HY-B0926S

Diatrizoic acid-d6 Diatrizoate-d₆; Amidotrizoic acid-d₆	Isotope-Labeled Compounds Apoptosis	Inflammation/Immunology
Diatrizoic acid-d₆ (Diatrizoate-d₆; Amidotrizoic acid-d₆) is the deuterium labeled Diatrizoic acid (HY-B0926). Diatrizoic acid (Diatrizoate) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Diatrizoic acid induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium .

HY-179052

Apoptosis inducer 50	Apoptosis Autophagy Bcl-2 Family Caspase Atg8/LC3 Atg7 CDK Reactive Oxygen Species (ROS)	Cancer
Apoptosis inducer 50 (Compound 5e) is an apoptosis inducer as well as an autophagy inducer agent. Apoptosis inducer 50 exhibits potent and selective anti-cancer activity against triple-negative breast cancer cells and metastatic colon cancer cells. Apoptosis inducer 50 upregulates the expression of pro-apoptotic proteins (Bax, Bim, cleaved Caspase-9) and downregulates the expression of the anti-apoptotic protein (BCL-XL). Apoptosis inducer 50 upregulates key autophagy markers such as Beclin-1 and ATG5, and enhances the conversion of LC3-I to LC3-II., Apoptosis inducer 50 arrests cancer cells in the G1/S phase by upregulating the expression of p21 and p27 while downregulating Cyclin D1. Apoptosis inducer 50 increases the level of ROS .

HY-117885

PF-5177624	PDK-1	Cancer
PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .

HY-A0170R

Trovafloxacin (Standard)	Reference Standards Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin (Standard) is the analytical standard of Trovafloxacin. This product is intended for research and analytical applications. Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-12502AR

Efonidipine hydrochloride monoethanolate (Standard) NZ-105 hydrochloride monoethanolate (Standard); (±)-Efonidipine hydrochloride monoethanolate (Standard)	Reference Standards Calcium Channel SARS-CoV	Cardiovascular Disease
Efonidipine (NZ-105) hydrochloride monoethanolate (Standard) is the analytical standard of Efonidipine hydrochloride monoethanolate (HY-12502AR). This product is intended for research and analytical applications. Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC₅₀ values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 main protease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .

HY-136682

N19-0881	Histone Demethylase	Cancer
N19-0881 (Compound 33) is an orally active, potent and selective KDM5A/5B histone lysine demethylase inhibitor (IC₅₀= 0.013 μM and 0.002 μM, respectively). N19-0881 is promising for research of epigenetically dysregulated tumors (e.g., breast cancer) .

HY-181532

IAP ligand 8	Ligands for E3 Ligase IAP	Cancer
IAP ligand 8 is an ASX-series, non-peptidic SMAC mimetic and IAP binder with high cell permeability. IAP ligand 8 selectively targets cIAP1-BIR3, XIAP-BIR2 (with a K_D of 15.8 nM for both). IAP ligand 8 serves as an IAP ligand moiety to synthesize IAP-recruiting protein degrader (IPD) (HY-181590). This IPD simultaneously forms two ternary complexes, cIAP1-A538-TEAD1 and XIAP-A538-TEAD1, and efficiently degrades TEAD1 via a dual E3 recruitment mechanism, while inducing the autodegradation of cIAP1. IAP ligand 8 and its series of degraders are applicable to targeted research on Hippo pathway-dysregulated cancers such as NF2-mutant mesothelioma .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library	2,491 compounds
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,491 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Anti-Colorectal Cancer Compound Library

2,491 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,491 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area	Image